Content preparation in progress
In January 2023, the 2,000㎡ workplace upgrade in Jin Chang'an, Beijing was completed.
In March 2023, the establishment of three MAH license-holding companies was completed, and the project establishment system centered on clear business models and stable supply chains was improved.
In April 2023, the strategic integration of CRO, CMO, and CSO for 4 active pharmaceutical ingredients was completed, upgrading the MAH service management ecosystem of Huayaoketron.
In June 2023, the independently developed pharmacovigilance system was launched, which can provide pharmacovigilance management services for the entire life cycle of drugs.
In August 2023, the scientific research achievement "Series of Innovations and Promotion Applications of the Occurrence Mechanism of Myocardial Injury and Key Technologies for Myocardial Protection" won the first prize of the "Invention and Entrepreneurship Award - Innovation Award" of the China Invention Association in 2023.
In May 2022, Huayaoketron was certified as a "Specialized, Sophisticated, Distinctive and Novel" small and medium-sized enterprise in Beijing for the first time.
In October 2022, the clinical research on the combined application scheme of traditional Chinese medicine with national secret formulas and biological preparations was initiated, marking that Huayaoketron has the experience of real-world research of all types.
In October 2022, the independently developed SMARTPHARM system covering the entire process management of pharmacy and clinical CRO business was launched, marking the realization of integrated and electronic management of the business of Huayaoketron.
In November 2022, four exclusive varieties covered by medical insurance were initiated for the "low-investment and full-process" MAH service, marking that the MAH service of Huayaoketron has entered the 3.0 mode.
In March 2021, Huayaoketron was certified as a Zhongguancun High-tech Enterprise for the first time.
In March 2021, Shandong Innovative Drug Laboratory began to operate, marking it's involvement in innovative drug research.
In June 2021, it participated in the establishment of the MAH license-holding company, marking that the MAH service of Huayaoketron has entered the 2.0 mode.
In September 2021, the sorting and positioning of the corporate culture was completed, marking that Huayaoketron has entered a development stage driven by the corporate culture as the core.
In November 2021, the renovation of the 1,000㎡ biological sample testing laboratory in Shenyang was completed, marking that the large and small molecule biological sample analysis and testing business of Huayaoketron has entered a stage of stable development.
In November 2021, the upgrade of the 5,000㎡ drug research laboratory in Shenyang was completed, marking that the pharmaceutical research business of Huayaoketron has entered a stage of rapid development.
In March 2020, Huayaoketron was certified as a science and technology-based small and medium-sized enterprise in Beijing for the first time.
In April 2020, the first clinical study of Class I biological preparations in the pediatric field was initiated, marking it's entry into the field of pediatric macromolecular preparations in its clinical research business.
In October 2020, Huayaoketron was certified as a high-tech enterprise for the first time.
In December 2020, the first clinical study of cell-based drugs was initiated, marking it's entry into the field of innovative technology treatment in clinical research business.
In February 2019, the National Resident Team for Clinical Research was established.
In October 2018, Huayaoketron Pharmaceutical Technology Development Co., Ltd. was established, integrating well-known CRO companies and advantageous resources to build the ecological chain of the entire life cycle of pharmaceutical and device technology services.
In December 2018, Shandong Huayao Pharmaceutical Technology Co., Ltd. was established to build a pharmaceutical research laboratory.
